

PROVA STRAFTA
SALVATORE BONVISA
17/02/2021
SF

CONCORSO PUBBLICO PER N. 1 POSTO DI DIRIGENTE MEDICO – AREA MEDICA E DELLE SPECIALITÀ MEDICHE – DISCIPLINA DI NEUROLOGIA – DA ASSEGNARE ALLA UOC NEUROLOGIA I – MALATTIA DI PARKINSON E DISTURBI DEL MOVIMENTO

PROVA ORALE N. 1

LE DISTONIE.

QUESITO DI INGLESE:

LETTURA E TRADUZIONE DI UNO STRALCIO DI ARTICOLO:

MR-guided focused ultrasound (MRgFUS), in combination with intravenous microbubble administration, has been applied for focal temporary BBB opening in patients with neurodegenerative disorders and brain tumors. MRgFUS could become a therapeutic tool for drug delivery of putative neurorestorative therapies. Treatment for Parkinson's disease with dementia (PDD) is an important unmet need. We initiated a prospective, single-arm, nonrandomized, proof-of-concept, safety and feasibility phase I clinical trial (NCT03608553), which is still in progress. The primary outcomes of the study were to demonstrate the safety, feasibility and reversibility of BBB disruption in PDD, targeting the right parieto-occipitotemporal cortex where cortical pathology is foremost in this clinical state. Changes in β amyloid burden, brain metabolism after treatments and neuropsychological assessments, were analyzed as exploratory measurements. Five patients were recruited from October 2018 until May 2019, and received two treatment sessions separated by 2–3 weeks. The results are set out in a descriptive manner. Overall, this procedure was feasible and reversible with no serious clinical or radiological side effects. We report BBB opening in the parieto-occipitotemporal junction in 8/10 treatments in 5 patients as demonstrated by gadolinium enhancement. In all cases the procedures were uneventful and no side effects were encountered associated with BBB opening. From pre- to post-treatment, mild cognitive improvement was observed, and no major changes were detected in amyloid or fluorodeoxyglucose PET. MRgFUS-BBB opening in PDD is thus safe, reversible, and can be performed repeatedly. This study provides encouragement for the concept of BBB opening for drug delivery to treat dementia in PD and other neurodegenerative disorders.

QUESITO DI INFORMATICA:

IL CANDIDATO INDICHI COME TRASFORMARE DATI NUMERICI IN UN GRAFICO

[Handwritten signatures]

PROVA ORALE
ESTRATTA
17/02/2023

CONCORSO PUBBLICO PER N. 1 POSTO DI DIRIGENTE MEDICO – AREA MEDICA E DELLE SPECIALITÀ MEDICHE – DISCIPLINA DI NEUROLOGIA – DA ASSEGNARE ALLA UOC NEUROLOGIA I – MALATTIA DI PARKINSON E DISTURBI DEL MOVIMENTO

PROVA ORALE N. 2

I TREMORI.

QUESITO DI INGLESE:


LETTURA E TRADUZIONE DI UNO STRALCIO DI ARTICOLO:

MR-guided focused ultrasound (MRgFUS), in combination with intravenous microbubble administration, has been applied for focal temporary BBB opening in patients with neurodegenerative disorders and brain tumors. MRgFUS could become a therapeutic tool for drug delivery of putative neurorestorative therapies. Treatment for Parkinson's disease with dementia (PDD) is an important unmet need. We initiated a prospective, single-arm, nonrandomized, proof-of-concept, safety and feasibility phase I clinical trial (NCT03608553), which is still in progress. The primary outcomes of the study were to demonstrate the safety, feasibility and reversibility of BBB disruption in PDD, targeting the right parieto-occipitotemporal cortex where cortical pathology is foremost in this clinical state. Changes in β amyloid burden, brain metabolism after treatments and neuropsychological assessments, were analyzed as exploratory measurements. Five patients were recruited from October 2018 until May 2019, and received two treatment sessions separated by 2–3 weeks. The results are set out in a descriptive manner. Overall, this procedure was feasible and reversible with no serious clinical or radiological side effects. We report BBB opening in the parieto-occipitotemporal junction in 8/10 treatments in 5 patients as demonstrated by gadolinium enhancement. In all cases the procedures were uneventful and no side effects were encountered associated with BBB opening. From pre- to post-treatment, mild cognitive improvement was observed, and no major changes were detected in amyloid or fluorodeoxyglucose PET. MRgFUS-BBB opening in PDD is thus safe, reversible, and can be performed repeatedly. This study provides encouragement for the concept of BBB opening for drug delivery to treat dementia in PD and other neurodegenerative disorders.

QUESITO DI INFORMATICA:

IL CANDIDATO INDICHI COME TRASFORMARE DATI NUMERICI IN UN GRAFICO



PROVA ORALE
NICO GOLFER- ANDREA S.
17/02/2021


CONCORSO PUBBLICO PER N. 1 POSTO DI DIRIGENTE MEDICO – AREA MEDICA E DELLE SPECIALITÀ MEDICHE – DISCIPLINA DI NEUROLOGIA – DA ASSEGNARE ALLA UOC NEUROLOGIA I – MALATTIA DI PARKINSON E DISTURBI DEL MOVIMENTO

PROVA ORALE N. 3

TERAPIE INTERVENTISTICHE PER LA MALATTIA DI PARKINSON.

QUESITO DI INGLESE:

LETTURA E TRADUZIONE DI UNO STRALCIO DI ARTICOLO:

MR-guided focused ultrasound (MRgFUS), in combination with intravenous microbubble administration, has been applied for focal temporary BBB opening in patients with neurodegenerative disorders and brain tumors. MRgFUS could become a therapeutic tool for drug delivery of putative neurorestorative therapies. Treatment for Parkinson's disease with dementia (PDD) is an important unmet need. We initiated a prospective, single-arm, nonrandomized, proof-of-concept, safety and feasibility phase I clinical trial (NCT03608553), which is still in progress. The primary outcomes of the study were to demonstrate the safety, feasibility and reversibility of BBB disruption in PDD, targeting the right parieto-occipitotemporal cortex where cortical pathology is foremost in this clinical state. Changes in β amyloid burden, brain metabolism after treatments and neuropsychological assessments, were analyzed as exploratory measurements. Five patients were recruited from October 2018 until May 2019, and received two treatment sessions separated by 2–3 weeks. The results are set out in a descriptive manner. Overall, this procedure was feasible and reversible with no serious clinical or radiological side effects. We report BBB opening in the parieto-occipitotemporal junction in 8/10 treatments in 5 patients as demonstrated by gadolinium enhancement. In all cases the procedures were uneventful and no side effects were encountered associated with BBB opening. From pre- to post-treatment, mild cognitive improvement was observed, and no major changes were detected in amyloid or fluorodeoxyglucose PET. MRgFUS-BBB opening in PDD is thus safe, reversible, and can be performed repeatedly. This study provides encouragement for the concept of BBB opening for drug delivery to treat dementia in PD and other neurodegenerative disorders.

QUESITO DI INFORMATICA:

IL CANDIDATO INDICHI COME TRASFORMARE DATI NUMERICI IN UN GRAFICO

